Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving transferase
Reexamination Certificate
2008-03-18
2008-03-18
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving transferase
C514S561000
Reexamination Certificate
active
07344851
ABSTRACT:
Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. α-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be designed to enhance affinity and/or specificity for a particular protein substrate.
REFERENCES:
patent: 5321053 (1994-06-01), Hino et al.
patent: 5504212 (1996-04-01), de Solms et al.
patent: 5602115 (1997-02-01), Nugent
patent: 5710171 (1998-01-01), Dinsmore et al.
patent: 5780437 (1998-07-01), Goulet et al.
patent: 5789427 (1998-08-01), Chen et al.
patent: 5859012 (1999-01-01), Dinsmore et al.
patent: 5886046 (1999-03-01), Hirschmann et al.
patent: 6083985 (2000-07-01), Yonemoto et al.
patent: 6284910 (2001-09-01), Spielmann et al.
patent: 6407071 (2002-06-01), Rubin
patent: 6576436 (2003-06-01), Rose et al.
patent: 0 512 865 (1992-11-01), None
Yang W. et al. Advances in the Development of Farnesyltransferase Inhibitors. J of Cellular Biochemistry Supplement 27:12-19, 1997.
Yonemoto M. et al. J-104,871, A Novel Farnesyltransferase Inhibitor . . . Molecular Pharmacology 54(1)1-7, 1998.
Sohn et al. “Chemical Modification Studies of Yeast Farnesyl Protein Transferase” J. Biochem Mol. Biol. vol. 30, No. 4, pp. 280-284, Jul. 31, 1997.
Barnard et al. “Characterization of Liver Prenyl Transferase and its Inactivation by Phenylglyoxal Biochimica et Biophysica Acts.” Feb. 22, 1980, vol. 617, No. 2, pp. 169-182.
Barnard et al. “Human Liver Prenyltransferase and its Characterization” Biochimica et Biophysica Acta. Sep. 15, 1981, vol. 661, No. 1, pp. 87-99.
Boivin et al. “Essential Arginine Residues in Isoprenylcysteine Protein Carboxyl Methyltransferase” Biochem. Cell Biol. 1977, vol. 75, No. 1, pp. 63-69.
Pande et al. (1980). Camphorquinone-10-sulfonic acid and derivatives; Convenient reagents for reversible modification of arginine residues. Proc. Natl. Acad. Sci. USA 77(2), pp. 895-899.
CAPLUS abstract (Acc No. 1970:520240), Schank et al. (1970). Alpha-hydroxy-beta-oxosulfones: Influence of conjugation and substitution effects. Chem. Ber. 103(10): pp. 3087-3092.
Mori et al. (1991). Preparative bioorganic chemistry. Synthesis 6: pp. 487-490.
Neidlein et al. (1996). Syntheses of 2,3-dioxoalkylphonates and other novel beta-ketophosphonates as well as of a phosphoinopyruvalhide. Helv. Chim. Acta 79(3): pp. 895-912.
Wedzicha et al. (1975). Concentrations of sulfonates derived from sulphite in certain foods. J. Sci. Fd. Agric. 26: pp. 327-335.
Renis H. Progress Antimicrobial Anticancer Chemother, Proc. Int. Congr. Chemother, 6th, 1970, Meeting Date 1969, vol. 2, 844-854.
Casey, P.J., Journal of Lipid Research, Biochemistry of protein prenylation, 1992, pp. 1731-1740, vol. 33.
Bos, J.L., Cancer Research,rasOncogenes in Human Cancer, A Review1, 1989, pp. 4682-4689, vol. 49.
Casey, P.J. et al., The Journal of Biological Chemistry, Protein Prenyltransferases, 1996, pp. 5289-5292, vol. 271.
Leonard, D.M., Journal of Medicinal Chemistry, Ras Farnesyltransferase: A New Therapeutic Target, 1997, pp. 2971-2990, vol. 40.
Gibbs, J.B. et al., Annu. Rev. Pharmacol. Toxicol. The Potential Of Farnesyltransferase Inhibitors As Cancer Chemotherapeutics1, 1997, pp. 143-166, vol. 37.
Cassidy, P.B. et al., Journal of Am. Chemical Society, Transition State Analogs for Protein Farnesyltransferase, 1996, pp. 8761-8762, vol. 118.
Patel, D.V. et al., Journal Med. Chem., Hydroxamic Acid-Based Bisubstrate Analog Inhibitors of Ras Farnesyl Protein Transferase, 1996, pp. 4197-4210, vol. 39.
Sattler, I., et al., “Prenylation of RAS and Inhibitors of Prenyltransferases.”, In Regulation of the RAS Signaling Network, H. Maruta and A.W. Burgess, eds., 1996, Chapter 4, Chapman & Halki, Austin, TX.
Huang, C.C., et al., The Journal Of Biological Chemistry, Evidence for a Catalytic Role of Zinc in Protein Farnesyltransferase, 1997, pp. 20-23, vol. 272.
Dolence, J.M., et al., Biochemistry, Yeast Protein Farnesyltransferase: Steady-State Kinetic Studies of Substrate Binding+, 1996, pp. 16687-16694, vol. 34.
Mu, Y.Q., et al., Journal of the American Chemical Society, On the Stereochemical Course of Human Protein-Farnesyl Transferase, 1996, pp. 1817-1823, vol. 118.
Park, H. W., et al., Science, Crystal Structure of Protein Farnesyltransferase at 2.25 Angstrom Resolution, 1997, pp. 1800-1804, vol. 275.
Dunten, P. et al., Biochemistry, Protein Farnesyltransferase: Structure and Implications for Substrate Binding, 1998, pp. 7907-7912, vol. 37.
Long, S.B., et al., Biochemistry, Cocrystal Structure of Protein Farnesyltransferase Complexed with a Farnesyl Diphosphate Substrate, 1998, pp. 9612-9618, vol. 37.
Takahashi, K., The Journal of Biological Chemistry, The Reaction of Phenylglyoxal with Arginine Residues in Proteins, 1968, pp. 6171-6179, vol. 243.
Pompliano, D.L., et al., J. Am. Chem. Soc., Intramolecular Fluorescence Enhancement: A Continuous Assay of Ras Farnesyl-Protein Transferase, 1992, pp. 7945-7946, vol. 114.
Patthy, L., et al., Eur. J. Biochem., Origin of the Selectivity of α-Dicarbonyl Reagents for Arginyl Residues of Anion-Binding Sites, 1980, pp. 387-393, vol. 105.
Rowell, C.A., et al., The Journal of Biological Chemistry, Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo, 1997, pp. 14093-14097, vol. 272.
Whyte, D.B., et al., The Journal Of Biological Chemistry, K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors, 1997, pp. 14459-14464, vol. 272.
Sattler, I. et al. Prenylation of RAS and Inhibitors of Prenyltransferases. Regulation of the RAS Signaling Network by Maruta and Burgess, R.G. Landes Co., Austin, TX, 1996.
Dedieu, M., C.R. Acad. Sc., Paris. vol. 282, Series C., pp. 65-67, 1976.
Stetter H. Synthesis. vol. 6, pp. 477-478, 1981.
Okolotowicz, K., Inactivation of Protein Farnesyltransferase by Active Site Targeted Dicarbonyl Compounds. Arch Pharm. Pharm. Med. Chem. 334(6)194-202, 2001.
Hartman Rosemarie F.
Lefler Scott
Okolotowicz Karl J.
Ottersberg Steven R.
Robinson Dale E.
Arizona Biomedical Research Commission
Banner & Witcoff , Ltd.
Gitomer Ralph
LandOfFree
Anticancer agents based on prevention of protein prenylation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticancer agents based on prevention of protein prenylation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer agents based on prevention of protein prenylation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2799804